In:
Liver International, Wiley, Vol. 34, No. 1 ( 2014-01), p. 136-146
Abstract:
Epigenetic alterations are well documented in hepatocarcinogenesis. However, hypomethylation of long interspersed nuclear element 1( LINE ‐1) promoter and its relationship with clinicopathological features in hepatocellular carcinoma ( HCC ) remain unknown. Methods The bisulfite‐specific PCR and DNA sequencing analysis was performed to assess the methylation status of LINE ‐1 promoter in a pilot cohort of 71 patients with HCC . Additionally, methylation levels of two hot CpG sites of LINE ‐1 promoter, site 7 and 18 were measured by real‐time PCR and compared with clinicopathological parameters in a cohort of 172 HCC . All the patients included were in BCLC stage A or B. Results Most patients with HCC (87.3%) showed hypomethylation of LINE ‐1 promoter compared with HBV ‐related cirrhosis and normal controls ( P 〈 0.001). The HCC patients with LINE ‐1 promoter hypomethylation had a median tumour‐free survival ( TFS ) and overall survival ( OS ) post‐resection of 22.0 (95% CI : 13.3–30.7) months and 35.0 (95% CI : 24.0–46.1) months, respectively, compared with 40 months and ~60 months for those with LINE ‐1 promoter hypermethylation ( P 〈 0.05). Multivariate analyses showed that the hypomethylation level at CpG site 7 and 18 of LINE ‐1 promoter, along with tumour size and tumour differentiation, was independently associated with both TFS and OS for patients with HCC after resection. Conclusion Promoter hypomethylation of LINE ‐1, especially at the CpG site 7 and 18, was associated with a poor prognosis in HCC .
Type of Medium:
Online Resource
ISSN:
1478-3223
,
1478-3231
DOI:
10.1111/liv.2013.34.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2124684-1
Permalink